"Proprotein Convertase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.
| Descriptor ID |
D000071449
|
| MeSH Number(s) |
D08.811.277.656.300.760.718 D08.811.277.656.837.688 D08.811.277.656.959.350.718
|
| Concept/Terms |
Proprotein Convertase 9- Proprotein Convertase 9
- Convertase 9, Proprotein
- Neural Apoptosis-Regulated Convertase 1
- Neural Apoptosis Regulated Convertase 1
- NARC-1 Protein
- NARC 1 Protein
- Proprotein Convertase, Subtilisin-Kexin Type 9
- Proprotein Convertase, Subtilisin Kexin Type 9
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertase 9".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertase 9".
This graph shows the total number of publications written about "Proprotein Convertase 9" by people in this website by year, and whether "Proprotein Convertase 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 4 | 2 | 6 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 6 | 7 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proprotein Convertase 9" by people in Profiles.
-
Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2024 04; 26(4):119-131.
-
LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon. J Am Coll Cardiol. 2024 02 13; 83(6):665-668.
-
Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of?siRNA Therapies for Prevention? J Am Coll Cardiol. 2023 12 12; 82(24):2262-2264.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
-
Detrimental effects of PCSK9 loss-of-function in the pediatric host response to sepsis are mediated through independent influence on Angiopoietin-1. Crit Care. 2023 06 26; 27(1):250.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 04 25; 81(16):1553-1564.
-
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. JAMA Cardiol. 2023 03 01; 8(3):258-267.
-
Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results. Circ Genom Precis Med. 2023 04; 16(2):e003816.